Last reviewed · How we verify
NCT04073953
Primaquine Enantiomers in G6PD Deficient Human Volunteers
Phase 1 trial testing RPQ in G6PD Deficiency in 18 participants. Completed in 1 September 2023.
1 September 2023
Quick facts
| Lead sponsor | University of Mississippi, Oxford |
|---|---|
| Phase | Phase 1 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | non randomized |
| Design | crossover |
| Masking | none |
| Primary purpose | basic science |
| Enrollment | 18 |
| Start date | 1 September 2020 |
| Primary completion | 1 September 2023 |
| Estimated completion | 1 September 2023 |
| Sites | 1 location across United States |
Drugs / interventions tested
Conditions studied
- G6PD Deficiency — all drugs for G6PD Deficiency →
Sponsor
University of Mississippi, Oxford
Who can join
Adults 18 to 65, any sex, with G6PD Deficiency. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study is a single center, prospective, cross-over phase 1 trial. Eighteen subjects will be enrolled in the study evaluating the metabolism, pharmacokinetic behavior and tolerability of primaquine enantiomers and placebo over the course of 5 days.
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
-
Enantioselective Interactions of Anti-Infective 8-Aminoquinoline Therapeutics with Human Monoamine Oxidases A and B.
Chaurasiya ND, Liu H, Doerksen RJ, Nanayakkara NPD, et al · · 2021 · cited 4× · PMID 33922294 · DOI 10.3390/ph14050398 -
Comparative metabolism and tolerability of racemic primaquine and its enantiomers in human volunteers during 7-day administration.
Khan W, Wang YH, Chaurasiya ND, Nanayakkara NPD, et al · · 2022 · cited 2× · PMID 36726785 · DOI 10.3389/fphar.2022.1104735
Verify or expand the search:
- PubMed search for NCT04073953
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of RPQ
Trials testing the same drug.
- NCT03934450 — Metabolism and Pharmacokinetics of Primaquine Enantiomers in Human Volunteers Receiving a Seven Day Dose Regimen · Phase 1 · completed
Other recruiting trials for G6PD Deficiency
Currently open trials in the same condition.
- NCT07468513 — Primaquine for Vivax Malaria in G6PD Intermediate and Deficient Cases. · Phase 4 · recruiting
Other University of Mississippi, Oxford trials
Trials by the same sponsor.
- NCT06695988 — Time-restricted Eating Acceptability, Efficacy and Safety in Obesity · NA · recruiting
- NCT05727332 — Vascular Adaptations to Single-Sprint Training · NA · completed
- NCT05908201 — Effects of Early Time Restricted Eating on Muscle Performance in Resistance Trained Individuals · NA · unknown
- NCT04280289 — CBD Cannabis Extract: Pharmacokinetic Studies · EARLY_PHASE1 · completed
- NCT04570917 — Online Education Intervention to Reduce Ageism Among Undergraduate Students · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04073953 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of Mississippi, Oxford
- Last refreshed: 21 November 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04073953.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing